Artiva (ARTV) Director Brian Daniels Receives 16,250-Share Award

What Happened Brian Daniels, a director of Artiva Biotherapeutics (ARTV), received a grant (derivative award) of 16,250 shares on September 10, 2026. The reported transaction shows an acquisition price of $0.00 (i.e., an option/award rather than a cash purchase); reported value at grant is $0 on the form. This is a standard equity compensation grant to a director, not a market sale or open-market purchase.

Key Details

• Transaction date: 2026-09-10; Form filed: 2026-09-14 (filed on time).
• Type: Grant / award (transaction code A); recorded as a derivative security (option).
• Quantity: 16,250 shares; reported price: $0.00.
• Vesting (footnote F1): The option will vest in full on the earlier of September 10, 2027, or the date of the issuer's 2027 annual stockholder meeting.
• Shares owned after transaction: not specified in the provided excerpt.
• No tax withholding, sale, or exercise was reported in this filing.

Context This was an equity compensation award (an option grant) to a director. Such grants are common as board compensation and are distinct from open-market purchases or sales — they do not represent an immediate cash investment or disposition by the insider. Because the award vests in the future, any potential trading or value realization would occur only after vesting and any subsequent exercise or sale.